MedicaidPrior AuthMedium impact
Talvey (talquetamab) (New)
Humana·LA · Oncology, Hematology·Medicaid
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicaid Louisiana has established a new prior authorization policy for Talvey (talquetamab), a specialty cancer drug for multiple myeloma patients. The policy requires approval for patients with relapsed/refractory multiple myeloma who have received at least four prior lines of therapy and meet specific clinical criteria.
Action Required
Before January 1, 2026: Billing team must update prior authorization procedures for Talvey (talquetamab) prescriptions for Louisiana Medicaid patients. Verify patients meet all four criteria including multiple myeloma diagnosis, relapsed/refractory disease, at least four prior therapies (anti-CD38 antibody, proteasome inhibitor, immunomodulatory agent), and single-agent use. Claims without prior authorization will be denied.